New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 8, 2013
21:06 EDTKPTIKaryopharm presents data for Selinexor at ASH
Karyopharm Therapeutics announced the oral presentation of clinical data from an ongoing Phase 1 clinical trial of its lead oral SINE compound, Selinexor, KPT-330, in patients with relapsed and/or refractory non-Hodgkin lymphoma, NHL, and chronic lymphocytic leukemia, CLL, at the 2013 American Society of Hematology, ASH, Annual Meeting and Exposition being held December 7-10 in New Orleans.The data indicate that, as of December 4, first-in-class oral Selinexor showed preliminary evidence of anti-cancer activity as a single agent in the majority of heavily pretreated relapsed and/or refractory NHL and CLL patients in the study cohort with progressive disease on study entry. In these NHL and CLL patients, Selinexor induced low levels of severe adverse events, and several of these patients have remained on study with Selinexor as their only anti-cancer treatment for more than 6-12 months.
News For KPTI From The Last 14 Days
Check below for free stories on KPTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
16:08 EDTKPTIKaryopharm announces initiation of Phase 1 study of Selinexor-decitabine combo
Karyopharm Therapeutics announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor in combination with the DNA methylation inhibitor decitabine in patients with relapsed or refractory acute myeloid leukemia, or AML, and in patients age 60 years with newly diagnosed AML. Sharon Shacham, Karyopharm's founder, President and Chief Scientific Officer, commented, "This first combination study of Selinexor represents a significant milestone for the company as we look to broaden the scope of SINE compounds in the treatment of cancers."
April 9, 2014
10:02 EDTKPTIKaryopharm enters into preferred provider agreement with Clinipace Worldwide
Clinipace Worldwide announced that Karyopharm Therapeutics has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases. As part of a long-term strategic partnership, Clinipace expects to manage numerous study starts on behalf of Karyopharm in 2014.
April 7, 2014
17:11 EDTKPTIKaryopharm requests withdrawal of registration statement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use